Sunovion Pharmaceuticals Inc., of Marlborough, Mass., reported results from the first placebo-controlled study of dasotraline for the treatment of adult patients with attention deficit hyperactivity disorder (ADHD) at the American College of Neuropsychopharmacology meeting in Phoenix.